How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

55,353 results for

Radiation Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines

Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines Effective Date: January 1, 2018 Proprietary Date of Origin: 05/14 (...) contained herein or not contained herein. Description and Application of the GuidelinesRadiation Oncology Image Guidance | Copyright © 2018. AIM Specialty Health. All Rights Reserved. 4 Modalities used in Image Guidance ? Ultrasound-based guidance ? Stereoscopic x-ray guidance ? CT based image guidance ? Real-time intrafraction guidance Radiation Oncology Considerations Image guidance, also known as image-guided radiation therapy (IGRT), refers to pre-treatment imaging used to verify correct patient

2018 AIM Specialty Health

4. Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. (PubMed)

Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. 29310183 2019 01 21 2019 01 21 1527-3792 199 1 2018 01 The Journal of urology J. Urol. Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus (...) Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. 28 S0022-5347(17)77695-1 10.1016/j.juro.2017.10.008 Taneja Samir S SS eng Journal Article Comment 2017 10 06 United States J Urol 0376374 0022-5347 0 Biomarkers AIM IM JAMA Oncol. 2017 May 1;3(5):652-658 28097317 Biomarkers Humans Male Prostatic Neoplasms 2018 1 10 6 0 2018 1 10 6 0 2019 1 22 6 0 ppublish 29310183 S0022-5347(17)77695-1 10.1016/j.juro.2017.10.008

2019 The Journal of urology

5. Radiation therapy with concurrent cisplatin versus radiation therapy with concurrent cetuximab in locally advanced HNSCC: a meta-analysis

Radiation therapy with concurrent cisplatin versus radiation therapy with concurrent cetuximab in locally advanced HNSCC: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler

2019 PROSPERO

6. ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update

ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 4, Pages 245–250 Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update (...) Accepted: February 19, 2018 ; Received: February 6, 2018 ; Abstract Purpose To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. Methods and materials Based on a systematic PubMed search showing new evidence for this key question, the task force felt an update was merited. Guideline

2019 American Society for Radiation Oncology

7. Radiation Therapy for the Whole-Breast (ASTRO)

Radiation Therapy for the Whole-Breast (ASTRO) Practical Radiation Oncology (2018) Radiation Therapy for the Whole Breast: An American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin D. Smith, MD, a* Jennifer R. Bellon, MD, b Rachel Blitzblau, MD, PhD, c Gary Freedman, MD, d Bruce Haffty, MD, e Carol Hahn, MD, f Francine Halberg, MD, g Karen Hoffman, MD, a Kathleen Horst, MD, h Jean M. Moran, PhD, i Caroline Patton, MA, j Jane Perlmutter, PhD, k Laura Warren, MD, b (...) in this guideline and that may, over time, be a basis for ASTRO to revisit and update the guideline. 3 ASTRO WHOLE BREAST IRRADIATION GUIDELINE Practical Radiation Oncology Introduction Breast cancer is the most common malignancy treated with radiation therapy (RT) in the United States, and whole breast irradiation (WBI) is the most common type of RT prescribed for breast cancer. 1 Historically, the standard of care for WBI in the United States has been conventional fractionation (CF), defined as daily doses

2019 American Society for Radiation Oncology

8. Review of Real-Time 3-Dimensional Image Guided Radiation Therapy on Standard-Equipped Cancer Radiation Therapy Systems: Are We at the Tipping Point for the Era of Real-Time Radiation Therapy? (PubMed)

Review of Real-Time 3-Dimensional Image Guided Radiation Therapy on Standard-Equipped Cancer Radiation Therapy Systems: Are We at the Tipping Point for the Era of Real-Time Radiation Therapy? To review real-time 3-dimensional (3D) image guided radiation therapy (IGRT) on standard-equipped cancer radiation therapy systems, focusing on clinically implemented solutions.Three groups in 3 continents have clinically implemented novel real-time 3D IGRT solutions on standard-equipped linear (...) coverage and variable normal tissue doses were found without real-time 3D IGRT. The geometric accuracy results with real-time 3D IGRT had a mean error of <0.5 mm and a standard deviation of <1.1 mm. Numerous additional articles exist that describe real-time 3D IGRT methods using standard-equipped radiation therapy systems that could also be clinically implemented.Multiple clinical implementations of real-time 3D IGRT on standard-equipped cancer radiation therapy systems have been demonstrated. Many

2018 Biology and Physics

9. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. (PubMed)

Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Historically, whole brain radiation therapy (WBRT) has been the main treatment for brain metastases. Stereotactic radiosurgery (SRS) delivers high-dose focused radiation and is being increasingly utilized to treat brain metastases. The benefit of adding SRS to WBRT is unclear. This is an updated version of the original Cochrane Review published in Issue 9, 2012.To assess the efficacy (...) studies, 129 participants; moderate-quality evidence). Furthermore, we observed an improvement in performance status scores and decrease in steroid use in the WBRT plus SRS group (risk ratio (RR) 0.64 CI 0.42 to 0.97; 1 study, 118 participants; low-quality evidence). Unchanged or improved Karnofsky Performance Scale (KPS) at six months was seen in 43% of participants in the combined therapy group versus only 28% in the WBRT-alone group (RR 0.78 CI 0.61 to 1.00; P value = 0.05; 1 study, 118

Full Text available with Trip Pro

2017 Cochrane

10. Spatial Dose Patterns Associated with Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Radiation Therapy with Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer. (PubMed)

Spatial Dose Patterns Associated with Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Radiation Therapy with Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer. Radiation pneumonitis (RP) is commonly associated with thoracic radiation therapy (RT), and its incidence is related to dose and volume of the normal lung in the path of radiation. Our aim was to investigate dose patterns associated with RP in patients enrolled in a randomized (...) trial of intensity-modulated RT (IMRT) versus passive scattering proton therapy (PSPT) for locally advanced non-small-cell lung cancer (NSCLC).We analyzed 178 patients prospectively treated with PSPT or IMRT for NSCLC to a prescribed dose of 66 or 74 Gy in conventional daily fractionation with concurrent chemotherapy. Forty patients (22%) developed clinically symptomatic RP. Voxel-based analysis (VBA) of local dose differences was done with a non-parametric permutation test accounting for multiple

2019 Biology and Physics

11. Comparison of 3D conformal radiation therapy and intensity-modulated radiation therapy in patients with endometrial cancer: efficacy, safety and prognostic analysis. (PubMed)

Comparison of 3D conformal radiation therapy and intensity-modulated radiation therapy in patients with endometrial cancer: efficacy, safety and prognostic analysis. Adjuvant whole-pelvic radiation therapy (WPRT) improves locoregional control for high-intermediate stages I-III endometrial cancer patients. Intensity modulated radiation therapy (IMRT) tends to replace the standard 3D conformal radiation therapy (3DCRT) technique used in trials.Consecutive patients with stages I-IIIc endometrial (...) cancer treated between 2008 and 2014 in our department with post-operative 3DCRT or IMRT WPRT were studied retrospectively. Patients with cervical involvement underwent additional low-dose rate vaginal brachytherapy. The impact of the WPRT technique on local control, tolerance, disease-free survival (DFS) and overall survival (OS) was assessed. Clinicians evaluated routinely acute radiation toxicity each week during radiation therapy and late toxicity during standard follow-up consultations.Median

2019 Acta Oncologica

12. Dental Management of Pediatric Patients Receiving Chemotherapy, Hematopoietic Cell Transplantation, and/or Radiation Therapy

Dental Management of Pediatric Patients Receiving Chemotherapy, Hematopoietic Cell Transplantation, and/or Radiation Therapy 392 RECOMMENDATIONS: BEST PRACTICES REFERENCE MANUAL V 40 / NO 6 18 / 19 Purpose The American Academy of Pediatric Dentistry (AAPD) recognizes that the pediatric dental professional plays an im- portant role in the diagnosis, prevention, stabilization, and treatment of oral and dental problems that can compromise the child’s quality of life before, during, and after (...) immuno- suppressive therapy which lowers the body’s normal immune response. This can be deliberate as in lowering the immune response to prevent the rejection of an organ or hematopoietic cell transplant* (HCT), or it can be incidental as in a side effect of chemotherapy, radiation therapy, or HCT conditioning. Dental intervention with certain modifications must be done promptly and efficiently, with attention to the patient’s medical history, treatment protocol, and health status. Immunosuppressive

2018 American Academy of Pediatric Dentistry

13. A comparison of dose distributions in gross tumor volume between boron neutron capture therapy alone and combined boron neutron capture therapy plus intensity modulation radiation therapy for head and neck cancer. (PubMed)

A comparison of dose distributions in gross tumor volume between boron neutron capture therapy alone and combined boron neutron capture therapy plus intensity modulation radiation therapy for head and neck cancer. Nine patients with recurrent head and neck (H&N) cancer received boron neutron capture therapy (BNCT) in one fraction at the Tsing-Hua Open pool reactor (THOR) utilizing the THORplan treatment planning system (TPS). The aims of the present study were to evaluate the use of intensity (...) modulated radiation therapy (IMRT) of 45 Gy in 20 fractions to compensate for the dose heterogeneity in gross tumor volume observed with single-fraction BNCT with mean prescription dose 19 Gy (w), and to evaluate planning quality indices of simulated BNCT+IMRT versus single-fraction BNCT alone. All IMRT plans were generated using the Eclipse TPS which employs the analytical anisotropic algorithm. The conformity index for the gross tumor volume (GTV) was better for the BNCT+IMRT plan than for the BNCT

Full Text available with Trip Pro

2019 PLoS ONE

14. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.01097 Journal of Clinical Oncology - published online before print October 11, 2018 Hypofractionated Radiation Therapy (...) Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Karen Hoffman, MD Anderson Cancer Center, Houston, TX; Mark K. Buyyounouski, Stanford University, Stanford; Palto Alto VA Health System, Palo Alto, CA; Caroline Patton, American Society for Radiation Oncology, Arlington, VA; Daniel Barocas, Vanderbilt University Medical Center, Nashville, TN; Soren Bentzen, University of Maryland School of Medicine, Baltimore, MD; Michael Chang, Hunter Holmes McGuire VA Medical Center and Virginia

2018 American Society of Clinical Oncology Guidelines

15. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Prostate Cancer: Hypofractionated Radiotherapy Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology (...) Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline (2018) Published 2018 The aim of this guideline is to present recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostate cancer. Panel Members Scott C

2018 American Urological Association

16. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.01097 Journal of Clinical Oncology - published online before print October 11, 2018 Hypofractionated Radiation Therapy (...) , ThedaCare Regional Cancer Center, Appleton, WI; and Howard Sandler, Cedars-Sinai Medical Center, Los Angeles, CA. INTRODUCTION Section: Background External beam radiation therapy (EBRT) is a standard definitive treatment option for men with localized prostate cancer and confers long-term prostate cancer control outcomes equivalent to radical prostatectomy. Improvements in imaging and computing over the past two decades have led to a number of technical advances in planning and delivery of prostate EBRT

2018 American Society of Clinical Oncology Guidelines

17. ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer

ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer Special Article Palliative thoracic radiation therapy for non- small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin Moeller MD, PhD a, ? , Ehsan H. Balagamwala MD b , Aileen Chen MD c , Kimberly M. Creach MD d , Giuseppe Giaccone MD, PhD e , Matthew Koshy MD f , Sandra Zaky MD, MS g , George Rodrigues MD, PhD, FASTRO h a Department of Radiation (...) Oncology Center, Turlock, California h Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada Received 6 February 2018; accepted 19 February 2018 Abstract Purpose: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. Methods

2018 American Society for Radiation Oncology

18. [Intensity-modulated radiation therapy for breast cancer]

[Intensity-modulated radiation therapy for breast cancer] [Intensity-modulated radiation therapy for breast cancer] [Intensity-modulated radiation therapy for breast cancer] Rodríguez B, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rodríguez B (...) , Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Intensity-modulated radiation therapy for breast cancer] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 525. 2017 Authors' conclusions No good quality evidence was found assessing the long-term effect of intensity-modulated radiation therapy for breast cancer. Low quality evidence (from one randomized

2017 Health Technology Assessment (HTA) Database.

19. Fraction size in radiation therapy for breast conservation in early breast cancer. (PubMed)

Fraction size in radiation therapy for breast conservation in early breast cancer. Shortening the duration of radiation therapy would benefit women with early breast cancer treated with breast conserving surgery. It may also improve access to radiation therapy by improving efficiency in radiation oncology departments globally. This can only happen if the shorter treatment is as effective and safe as conventional radiation therapy. This is an update of a Cochrane Review first published in 2008 (...) and relevant conference proceedings. No language or publication constraints were applied.Randomised controlled trials of altered fraction size versus conventional fractionation for radiation therapy in women with early breast cancer who had undergone breast conserving surgery.Two authors performed data extraction independently, with disagreements resolved by discussion. We sought missing data from trial authors.We studied 8228 women in nine studies. Eight out of nine studies were at low or unclear risk

Full Text available with Trip Pro

2016 Cochrane

20. Hyperbaric oxygen therapy for late radiation tissue injury. (PubMed)

Hyperbaric oxygen therapy for late radiation tissue injury. Cancer is a significant global health problem. Radiotherapy is a treatment for many cancers and about 50% of people having radiotherapy will be long-term survivors. Some will experience late radiation tissue injury (LRTI) developing months or years later. Hyperbaric oxygen therapy (HBOT) has been suggested as a treatment for LRTI based upon the ability to improve the blood supply to these tissues. It is postulated that HBOT may result (...) for an additional beneficial outcome (NNTB) 5; 246 participants, 3 studies). There was also moderate quality evidence of a significantly improved chance of wound breakdown without HBOT following operative treatment for ORN (RR 4.2; 95% CI 1.1 to 16.8, P value = 0.04, NNTB 4; 264 participants, 2 studies). From single studies there was a significantly increased chance of improvement or cure following HBOT for radiation proctitis (RR 1.72; 95% CI 1.0 to 2.9, P value = 0.04, NNTB 5), and following both surgical

Full Text available with Trip Pro

2016 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>